By Metrologie Solutions Philippines   |   Expert Pharmaceutical Metrology Services   |   Updated 2025

Every pharmaceutical company, drug distributor, importer, and cold chain logistics provider operating in the Philippines faces the same non-negotiable reality: the products they handle — medicines, biologics, vaccines, and other time- and temperature-sensitive pharmaceutical products — must be stored within precise temperature ranges from the moment they arrive in the country until the moment they reach the patient.

This is not a best practice. It is a legal requirement, enforced by the Food and Drug Administration of the Philippines, aligned with the World Health Organization’s Good Distribution Practice guidelines, and embedded in the Good Manufacturing Practice frameworks that govern the entire Philippine pharmaceutical industry.

At the heart of this compliance obligation is thermal mapping — the scientific validation process that proves, with documented data, that your pharmaceutical warehouse, cold room, or storage facility actually maintains the required temperatures throughout its entire volume, under real operating conditions, at all relevant times of the year.

This guide is written for Philippine pharmaceutical companies, drug distributors, hospital pharmacies, and cold chain operators who need a complete, accurate, and actionable understanding of what thermal mapping requires, what the Philippine FDA and WHO expect, and how to implement a thermal mapping program that will satisfy the most rigorous regulatory inspection. It covers the regulatory framework in full, explains every phase of the mapping process, and provides the practical guidance needed to protect both your products and your licence to operate.

What This Article AnswersWhat does FDA Circular No. 2021-003 actually require for warehouse temperature validation?What do WHO Good Distribution Practice guidelines say about thermal mapping?What are the specific temperature ranges Philippine pharma warehouses must maintain?How is a pharmaceutical warehouse thermal mapping study conducted, step by step?What documentation do you need to present at an FDA inspection?How often must you repeat a mapping study, and when does the law require it immediately?

1. Why Pharmaceutical Warehouse Temperature Control Is Non-Negotiable in the Philippines

The Philippines is a tropical archipelago with average temperatures of 26°C to 32°C, humidity regularly exceeding 80%, significant seasonal variation between the dry season and the wet monsoon season, and a power infrastructure that — particularly outside Metro Manila — remains susceptible to interruptions. These conditions create one of the most challenging environments in Southeast Asia for pharmaceutical cold chain management.

Drug products are sensitive to temperature in ways that are often invisible. A batch of insulin exposed to 15°C for three hours instead of the required 2°C to 8°C may look and smell identical to an undamaged batch — but its efficacy may have been irreversibly reduced. Vaccines that have experienced a freeze event may appear visually normal but be entirely inactive. Biologics degraded by a prolonged temperature excursion in a warehouse will reach patients who believe they are receiving effective treatment.

The consequences of temperature failure in the pharmaceutical supply chain are therefore not merely regulatory — they are clinical. Patients receive ineffective or unsafe medicines. Healthcare providers make clinical decisions based on treatments that no longer work. Public health programmes — vaccination campaigns, disease management initiatives — fail silently because the drugs used have lost their potency somewhere in the supply chain.

This is why the Philippine FDA, the WHO, and every serious pharmaceutical quality standard in the world treat temperature control not as a preference but as a core product quality obligation — one that must be validated before a storage area is used, and monitored continuously throughout its operational life.

The Scale of the Risk in the Philippine Pharmaceutical Sector

The Philippine pharmaceutical market is one of the largest in Southeast Asia. Billions of pesos of temperature-sensitive drug products move through Philippine warehouses, distribution centres, and hospital pharmacies every year. These include refrigerated biologics, insulin products, vaccines for national immunisation programmes, oncology drugs, diagnostic reagents, blood products, and a rapidly growing portfolio of specialty medicines.

Any failure in temperature control along this supply chain — a hot spot in a warehouse that has never been mapped, a cold room whose sensors are placed in the wrong location, a distribution truck that was never thermally qualified — creates direct patient safety risk and exposes the company responsible to regulatory sanctions, product recalls, and civil liability.

The Philippine FDA’s increasing enforcement activity in this area reflects a maturing regulatory environment. Establishments seeking or renewing their Licence to Operate are scrutinised more closely than ever before. And the international pharmaceutical companies whose products are distributed in the Philippines increasingly require their local distribution partners to demonstrate thermal mapping compliance as a condition of their agreements.

The Business Risk Is RealFailure to comply with Philippine FDA temperature storage requirements can result in suspension or revocation of your Licence to Operate, mandatory product recalls, financial penalties, and reputational damage that can permanently affect your business relationships with multinational pharmaceutical principals.Investing in proper thermal mapping is not a cost — it is risk mitigation for an asset that may be worth billions of pesos over the life of your pharmaceutical distribution business.

2. The Philippine Regulatory Framework: What FDA and WHO Actually Require

Understanding exactly what the regulations require — and what authority they carry — is the foundation of any effective pharmaceutical warehouse thermal mapping programme. Here is a complete and accurate account of the regulatory framework as it applies to Philippine pharmaceutical establishments in 2025.

FDA Circular No. 2021-003: Revised Guidelines on Cold Chain Management

FDA Circular No. 2021-003, issued by the Food and Drug Administration of the Philippines and titled ‘Revised Guidelines on Cold Chain Management for Pharmaceutical Products and Establishments,’ is the primary domestic regulatory reference for temperature control of pharmaceutical products in the Philippines.

This circular applies to all establishments handling pharmaceutical products that require temperature-controlled storage or distribution — including manufacturers, importers, exporters, wholesalers, distributors, and retail pharmaceutical outlets. Its requirements establish the minimum standards that must be met for a pharmaceutical establishment to obtain or renew its Licence to Operate (LTO).

Among its key provisions, FDA Circular 2021-003 requires that all temperature-controlled storage areas used for pharmaceutical products are properly qualified before use. This qualification must demonstrate — through a documented study — that the storage area is capable of maintaining the required temperature conditions throughout its entire volume under normal operating conditions. This requirement for documented qualification is the regulatory basis for thermal mapping in Philippine pharmaceutical facilities.

The circular also requires continuous temperature monitoring of all storage areas during operations, calibration of all monitoring equipment, and maintenance of complete temperature records that must be available for FDA inspection.

Administrative Order No. 2024-0015: Updated LTO Requirements

Administrative Order No. 2024-0015, implemented from January 2025, updated the rules and requirements for Licence to Operate applications across all health product establishments registered with the Philippine FDA. Drug distributors, importers, exporters, wholesalers, and pharmaceutical outlets are among the establishments covered. LTO applicants must demonstrate compliance with all applicable quality and technical standards — including those for temperature-controlled storage — as part of the licensing process.

This means that thermal mapping documentation is not merely an internal quality requirement. It is a prerequisite for obtaining and maintaining the legal authority to operate as a pharmaceutical establishment in the Philippines.

WHO Good Distribution Practice: TRS 961 Annex 9

The World Health Organization’s Model Guidance for the Storage and Transport of Time- and Temperature-Sensitive Pharmaceutical Products, published in WHO Technical Report Series No. 961 (Annex 9), is the global reference standard for pharmaceutical storage qualification. The Philippine FDA explicitly references WHO Good Distribution Practice guidelines in its cold chain management requirements, making compliance with WHO TRS 961 an integral part of Philippine pharmaceutical regulatory compliance.

WHO TRS 961 Annex 9 states unambiguously: ‘Qualify new temperature-controlled storage areas and new refrigeration equipment before it becomes operational.’ The qualification procedure required by WHO must: demonstrate the air temperature profile throughout the storage area or equipment cabinet, when empty and in a normal loaded condition; define zones which should not be used for storage of time- and temperature-sensitive pharmaceutical products; and demonstrate the time taken for temperatures to exceed the designated limits when cooling equipment fails.

These requirements form the scientific and technical specification for what a WHO-compliant thermal mapping study must achieve. WHO TRS 961 also requires that additional qualification exercises be carried out whenever modifications are made to the storage area that may affect temperature distribution, and that calibration devices be verified against certified, traceable reference standards at least once a year.

WHO TRS 961 Supplement 8: Temperature Mapping of Storage Areas

Supplement 8 to WHO TRS 961, titled ‘Temperature Mapping of Storage Areas,’ provides the most detailed WHO technical guidance specifically on how thermal mapping studies must be conducted. It specifies requirements for study protocol development, the selection and calibration of temperature data loggers, sensor placement principles, study duration, data analysis methodology, and report documentation.

Supplement 8 is the document that professional thermal mapping service providers use as the technical standard for study design. It is also the document that well-prepared FDA inspectors reference when evaluating the adequacy of a pharmaceutical establishment’s thermal mapping documentation.

WHO TRS 1010 Annex 7: Good Storage and Distribution Practices for Medical Products

Published in 2021, WHO Technical Report Series No. 1010 Annex 7 updated and strengthened the requirements for pharmaceutical storage and distribution. It reinforces the requirement for thermal mapping of storage areas as part of facility qualification, and adds further emphasis on the need for transport temperature verification — making it clear that warehouse mapping and transport lane qualification should be conducted using consistent methodologies.

Good Manufacturing Practice (GMP) Requirements

For pharmaceutical manufacturers operating in the Philippines — whether producing for the domestic market or for export — Good Manufacturing Practice guidelines require validation of all critical systems and processes, including temperature-controlled storage. Under GMP frameworks, thermal mapping is part of the Installation Qualification, Operational Qualification, and Performance Qualification (IQ/OQ/PQ) lifecycle for cold rooms, refrigerators, freezers, and climate-controlled warehouses.

GMP also requires that monitoring equipment be calibrated, that deviations from specified conditions be investigated, and that corrective and preventive actions be documented. These requirements apply throughout the product lifecycle and must be reflected in the pharmaceutical establishment’s quality management system.

ISPE Good Practice Guide: Controlled Temperature Chambers (2nd Edition, 2021)

The International Society for Pharmaceutical Engineering’s Good Practice Guide for Controlled Temperature Chambers — updated in December 2021 — is the industry’s technical reference for commissioning, qualification, mapping, and monitoring of pharmaceutical temperature-controlled storage. While it carries no direct legal authority in the Philippines, it is the standard against which multinational pharmaceutical companies evaluate their Philippine distribution partners, and it provides the detailed technical framework for conducting mapping studies of the highest professional quality.

Regulation / Guideline	Issued By	Key Thermal Mapping Requirement
FDA Circular No. 2021-003	FDA Philippines	Cold chain qualification of storage areas before use; continuous monitoring; calibration of equipment; complete temperature records
AO No. 2024-0015	FDA Philippines	Compliance with temperature storage standards required for LTO issuance and renewal for all drug establishments
WHO TRS 961 Annex 9	World Health Org.	Mandatory qualification of all new temperature-controlled storage areas; qualification after modifications; calibrated sensors; full documentation
WHO TRS 961 Supplement 8	World Health Org.	Detailed protocol requirements; sensor placement; study duration; data analysis; report format for temperature mapping studies
WHO TRS 1010 Annex 7 (2021)	World Health Org.	Updated GSD P standards; strengthened transport temperature verification; consistent mapping methodology for warehouses and transport
GMP (PIC/S, WHO)	PIC/S / WHO	IQ/OQ/PQ qualification lifecycle for storage areas; monitoring equipment calibration; deviation investigation; CAPA documentation
ISPE GPG CTC 2nd Ed. (2021)	ISPE	Technical standard for commissioning, qualification, mapping and monitoring of controlled temperature chambers; used by multinational pharma principals

3. Philippine Pharmaceutical Temperature Storage Requirements

Before conducting a thermal mapping study, a pharmaceutical warehouse must define its acceptance criteria — the temperature range that the space must maintain throughout its entire volume. These acceptance criteria are determined by the products being stored, and they are governed by the product labels, manufacturer specifications, and the relevant pharmacopeial standards.

Here is a reference table of the standard temperature storage categories applicable to pharmaceutical products in the Philippines, aligned with Philippine FDA, WHO, and USP requirements:

Storage Category	Temperature Range	Common Products	Philippine FDA / WHO Reference
Controlled Room Temperature (CRT)	20°C to 25°C (excursions 15°C–30°C permitted)	Oral solids, topicals, most OTC medicines	USP <659>; WHO GDP; FDA storage labelling requirements
Cool Storage	8°C to 15°C	Some liquid preparations, specific reagents	USP storage definitions; product-specific requirements
Refrigerated Storage	+2°C to +8°C	Vaccines, insulin, biologics, some antibiotics	FDA Circular 2021-003; WHO TRS 961; DOH cold chain guidelines
Frozen Storage	-20°C to -10°C	Plasma, some biologics, certain vaccines	WHO cold chain standards; product manufacturer requirements
Ultra-Cold / Deep Frozen Storage	-80°C to -60°C	mRNA vaccines, gene therapy products, some biologics	Product-specific requirements; WHO guidance for biologics
Controlled Ambient Temperature	15°C to 30°C	Most ambient-temperature pharmaceuticals	WHO GDP; GMP storage validation requirements

Critical Note on Excursion LimitsThe permitted temperature excursions defined in pharmacopeial standards (such as USP <659> which allows brief excursions between 15°C and 30°C for CRT products) apply only to brief, accidental deviations — not to the systematic design of storage areas.Your thermal mapping acceptance criteria must be set at the primary storage temperature requirement, not at the excursion limit. A warehouse mapped to demonstrate that temperatures remain within 15°C to 30°C is not compliant for CRT storage — it must demonstrate consistent maintenance within 20°C to 25°C as the primary condition.

4. Step-by-Step: How a Pharmaceutical Warehouse Thermal Mapping Study Works

A pharmaceutical warehouse thermal mapping study is a structured, documented process that follows a defined lifecycle. The following phases represent the WHO- and GMP-compliant methodology used by professional thermal mapping service providers for Philippine pharmaceutical establishments.

Phase 1: Scope Definition and Risk Assessment

Every pharmaceutical warehouse thermal mapping study begins with a clear definition of what is being mapped, why, and under what conditions. The scope definition addresses: the physical boundaries of the storage area to be mapped, the temperature category applicable to the products stored (CRT, refrigerated, frozen, or ambient), the regulatory standards the study must meet (FDA Circular 2021-003, WHO TRS 961 Supplement 8, GMP requirements), and any specific risk factors for the facility — such as external walls exposed to direct sunlight, areas near loading docks, or known HVAC weaknesses.

A risk assessment at this stage identifies the zones most likely to exhibit temperature extremes — corners near doors, areas adjacent to cooling coils or fans, zones near external walls — and ensures the study design includes adequate sensor coverage of these high-risk areas. This risk-based approach is explicitly recommended by WHO TRS 961 and the ISPE Good Practice Guide.

Phase 2: Protocol Development and Approval

The study protocol is the governing document of the thermal mapping exercise. It must be written and approved before any equipment is deployed. A GMP- and WHO-compliant thermal mapping protocol for a Philippine pharmaceutical warehouse contains:

• Study objectives and scope — clearly stating what the study intends to prove and what storage area is covered
• Regulatory references — specifying which FDA, WHO, GMP, and ISPE standards the study is designed to meet
• Acceptance criteria — the specific temperature range that all sensors must remain within throughout the study period
• Equipment list — all data loggers to be used, their calibration status, and serial numbers
• Sensor placement rationale — a detailed justification for the number and position of every sensor, referenced to the risk assessment and WHO sensor density guidance
• Study conditions — whether the study will be conducted loaded or unloaded (or both), the HVAC operating conditions, and any door operation protocols
• Study duration — the minimum time the sensors will be deployed, with justification
• Data analysis methodology — how the data will be processed and reported
• Approval signatures — the protocol must be approved by a qualified person or QA manager before the study begins

Phase 3: Equipment Calibration

All data loggers used in the thermal mapping study must be calibrated immediately before deployment. This is a mandatory requirement under WHO TRS 961 Supplement 8 and GMP standards. Calibration must:

• Be performed by a laboratory accredited by the Philippine Accreditation Bureau (PAB) to ISO/IEC 17025, ensuring international traceability of the measurement results
• Cover the full temperature range expected during the study (for example, 0°C to 10°C for a refrigerated warehouse, or 15°C to 35°C for a CRT warehouse)
• Produce a calibration certificate for each data logger, showing the reference standard used, the measured values at each test point, any corrections to be applied, and the measurement uncertainty
• Be performed within a timeframe that ensures the calibration is current at the time of the study (typically not more than one year for routine monitoring, or ideally immediately before the study for mapping applications)

Post-study calibration — verifying that the data loggers remain within specification after the study period — is also best practice and provides additional assurance that the data collected during the study is valid.

Phase 4: Sensor Placement

The placement of temperature sensors is one of the most technically important decisions in the thermal mapping study. Sensors placed incorrectly will miss hot spots and cold spots, producing a misleading picture of the warehouse temperature profile.

WHO TRS 961 Supplement 8 provides guidance on the minimum number of sensors based on the volume of the storage area. As a general principle, sensors must be placed:

1. At all eight geometric extremes of the space (the eight corners of the three-dimensional volume)
2. At the identified hot spots — areas expected to be warmest, such as near the loading dock door, near exterior walls with sun exposure, or in areas with limited airflow
3. At the identified cold spots — areas expected to be coldest, such as near cooling coil outlets or fan discharge points
4. At mid-height in the centre of the space, to capture the main body temperature
5. At multiple height levels where height stratification is a known or suspected risk — typically near the floor, at mid-height, and near the ceiling
6. Next to any existing permanent monitoring sensor, to verify that the permanent sensor’s readings are representative

For large pharmaceutical warehouses, the number of sensors may be significant. WHO guidance suggests a minimum of 16 sensors for spaces between approximately 70 and 700 square feet, with additional sensors required for larger or more complex spaces.

Phase 5: Data Collection Under Representative Conditions

With sensors in place, the study runs for its full planned duration. WHO TRS 961 Supplement 8 specifies that the study duration must be sufficient to capture representative operating conditions. For pharmaceutical warehouses, this typically means:

• A minimum of 24 to 72 hours for smaller cold rooms and refrigerated units
• Five to seven days for larger warehouses to capture full operating cycles, shift changes, loading and unloading events, and diurnal temperature variation
• Extended studies in some cases to capture weekend or low-activity conditions that differ from peak operating days

The study should be conducted under conditions that represent the most thermally challenging scenario the warehouse will face. For a new warehouse, this typically means conducting studies in both an empty/unloaded condition (to characterise baseline airflow and temperature distribution) and a loaded condition (to understand how product thermal mass affects temperature distribution). Both WHO TRS 961 and the ISPE Good Practice Guide distinguish between Operational Qualification mapping (empty or minimally loaded) and Performance Qualification mapping (fully loaded under normal operating conditions).

For Philippine pharmaceutical warehouses, this also means conducting studies during both the dry season (March to May, when ambient temperatures peak) and the wet season (July to September, when humidity is highest and ambient conditions are different). WHO TRS 961 Supplement 8 explicitly requires that seasonal variations be taken into account. A warehouse that qualifies easily in December may fail in April. Seasonal mapping is not optional — it is a WHO requirement and an FDA expectation.

The Philippine Seasonal Mapping RequirementThe Philippines experiences significant seasonal variation in ambient temperature and humidity. WHO TRS 961 Supplement 8 requires that thermal mapping studies take seasonal variations into account.This means pharmaceutical warehouses in the Philippines must conduct mapping studies in at least two seasons — the hot dry season (typically March to May) and the wet season (typically July to September). Studies conducted in only one season provide incomplete qualification and may be challenged during FDA inspections.Metrologie Solutions Philippines includes dual-season mapping as a standard recommendation for all pharmaceutical warehouse qualification programmes.

Phase 6: Data Analysis and Hot/Cold Spot Identification

Once the study period is complete, all data loggers are retrieved and their data is downloaded and analysed. The analysis produces:

• Minimum, maximum, mean, and standard deviation of temperature for each sensor location
• The overall minimum and maximum temperature recorded anywhere in the warehouse during the study period
• Identification of the hot spot location — the sensor that recorded the highest temperature or the most frequent excursions above the upper acceptance limit
• Identification of the cold spot location — the sensor that recorded the lowest temperature or the most frequent excursions below the lower acceptance limit
• Temperature uniformity analysis — the difference between the maximum and minimum mean temperatures across all sensors
• Time-above-limit and time-below-limit analysis — how long, if at all, any sensor exceeded the acceptance criteria
• Mean Kinetic Temperature (MKT) calculations where required for ambient temperature warehouses

The hot spot and cold spot identified by this analysis are the two most important outputs of the thermal mapping study — because these are the locations where permanent monitoring sensors must be placed to provide the most meaningful, worst-case temperature surveillance during ongoing operations.

Phase 7: Power Failure and Contingency Testing

WHO TRS 961 Annex 9 requires that thermal mapping studies demonstrate the time taken for temperatures to exceed the designated limits when cooling equipment fails. This power failure simulation — also called a temperature excursion test — is conducted as part of the mapping study by interrupting cooling temporarily and monitoring how quickly temperatures rise to the out-of-specification limit.

The data from this test is used to define the maximum allowable response time for temperature excursions — the window within which your operations team must respond to a cooling failure before product is at risk. This information directly informs your Temperature Excursion Response Standard Operating Procedure.

Phase 8: Report Development and Qualification Decision

The thermal mapping report is the formal record of the entire study. For a Philippine pharmaceutical establishment, this document is the evidence of compliance that will be reviewed by FDA inspectors, multinational pharmaceutical principals, and quality auditors. A complete, GMP-quality thermal mapping report contains:

• Executive summary — study objectives, dates, overall conclusion (pass or fail)
• Protocol reference and approval record — confirming the study was conducted according to the approved protocol
• Facility and equipment description — layout drawing with sensor positions marked
• Equipment calibration certificates — for all data loggers used, pre-study (and ideally post-study)
• Raw data — complete temperature records from all sensors for the full study period
• Statistical analysis — min, max, mean, standard deviation, MKT for each sensor and overall
• Hot spot and cold spot identification — with clear sensor location references
• Excursion analysis — any out-of-limit events, their duration and likely cause
• Power failure test results — time to temperature excursion limit
• Permanent monitoring sensor placement recommendations — based on hot and cold spot analysis
• Conclusions — whether the warehouse meets the acceptance criteria
• Required actions — corrective actions if the study fails, or recommendations for ongoing compliance
• Qualified Person / QA Manager approval signature

5. After the Mapping Study: Building Your Ongoing Compliance System

A thermal mapping study that qualifies your pharmaceutical warehouse is the beginning of your temperature compliance programme, not the end. The regulatory frameworks that govern Philippine pharmaceutical establishments require not just qualification but ongoing maintenance of that qualified state.

Positioning Permanent Monitoring Sensors

The immediate post-mapping action is to position permanent temperature monitoring sensors at the hot spot and cold spot identified by the mapping study. These locations are the worst-case positions in your warehouse — the places where temperature is most likely to go out of specification first. Monitoring the worst case means you get the earliest possible warning of a temperature problem before it affects products in more moderate zones.

If your existing permanent monitoring sensors are not located at the hot spot and cold spot, they must be relocated. This is one of the most common corrective actions following a first thermal mapping study of a warehouse that has been operating with monitoring but without prior mapping.

Calibration Schedule for Monitoring Equipment

WHO TRS 961 requires that temperature monitoring devices be calibrated against a certified, traceable reference standard at least once a year, unless otherwise justified. For high-risk pharmaceutical products — vaccines, biologics, oncology drugs — more frequent calibration (every six months) is recommended and increasingly expected by regulatory inspectors and multinational pharmaceutical principals.

Calibration records must be maintained and available for inspection. Each calibration certificate must show traceability through a PAB-accredited calibration laboratory to national and international measurement standards.

Standard Operating Procedures for Temperature Excursions

Every pharmaceutical warehouse must have a written, validated, and trained Standard Operating Procedure (SOP) for responding to temperature excursions. This SOP must define: the alarm threshold at which staff are notified, the responsible personnel and their contact details, the maximum response time before corrective action must be taken, the steps for investigating the cause of the excursion, the criteria for quarantining affected products, and the process for assessing whether quarantined products can be released or must be destroyed.

The power failure test data from the mapping study informs the response time in this SOP — you now know exactly how long you have before product temperature exceeds the acceptable limit, and your response time must be shorter than this window.

Change Control and Remapping Obligations

Any significant change to the pharmaceutical warehouse — its physical structure, HVAC system, layout, loading patterns, or product mix — may invalidate the existing thermal mapping qualification. Philippine FDA regulations and WHO Good Distribution Practice require that qualification exercises be repeated whenever modifications are made to the storage area that may affect temperature distribution.

Your quality management system must include a change control process that evaluates proposed changes to the warehouse for their potential impact on temperature distribution, and triggers a remapping study when the impact assessment indicates that temperature behaviour may be affected.

Periodic Requalification

Even without specific changes, most GMP quality systems require periodic requalification of validated storage areas — typically every one to two years for pharmaceutical cold rooms, or every two to three years for ambient temperature warehouses, depending on the criticality of the products stored. Your quality system should define the requalification interval appropriate for your products and regulatory context, and maintain a schedule ensuring that remapping studies are planned and executed before the current qualification expires.

Best Practice for Philippine Pharmaceutical WarehousesMetrologie Solutions Philippines recommends the following minimum programme for pharmaceutical warehouse thermal mapping compliance in the Philippines:1. Initial qualification mapping study before first use (loaded and unloaded conditions)2. Seasonal remapping — dry season (March to May) and wet season (July to September) — for the first two years of operation3. Annual requalification thereafter, or immediately after any structural or HVAC change4. Annual calibration of all permanent monitoring sensors by a PAB-accredited laboratory5. All mapping documentation retained for the life of the warehouse plus a minimum of five years

6. Types of Pharmaceutical Storage Areas That Require Thermal Mapping in the Philippines

Thermal mapping requirements apply across the full range of temperature-controlled storage environments used by Philippine pharmaceutical establishments. Here is guidance on the specific requirements for each type.

Pharmaceutical Cold Rooms (2°C to 8°C)

Cold rooms storing vaccines, biologics, insulin, and other refrigerated pharmaceutical products are the most heavily regulated storage environment in the Philippine pharmaceutical sector. They must be fully qualified — with thermal mapping in both loaded and unloaded conditions — before any pharmaceutical products are stored. Seasonal mapping is mandatory given the Philippine climate. Power failure testing is required. All permanent monitoring sensors must be positioned at the hot and cold spots identified by mapping.

For hospital pharmacies and clinics operating smaller pharmaceutical refrigerators, the same principles apply. Individual pharmaceutical refrigerators used to store regulated products must be mapped or at minimum temperature-distribution qualified before use. Many multinational vaccine manufacturers now require distribution partners to provide mapping documentation for every refrigerator unit in their distribution network.

Ambient Temperature (Controlled Room Temperature) Warehouses

Controlled Room Temperature warehouses storing the majority of pharmaceutical products — oral solids, topicals, OTC products, most prescription medicines — must maintain temperatures between 20°C and 25°C consistently throughout the storage area. In the Philippine climate, this is a significant challenge for large warehouses, particularly during the summer months when ambient temperatures frequently exceed 35°C.

Thermal mapping of CRT warehouses in the Philippines must include summer season mapping (March to May) to demonstrate that the HVAC system can maintain temperatures within the 20°C to 25°C range even at peak ambient temperatures. This is the most common failure point in Philippine pharmaceutical warehouse thermal mapping — the warehouse maintains adequate temperatures in December but cannot sustain them in April.

The HVAC system design, capacity, and maintenance must be validated as part of the warehouse qualification programme. Areas near loading docks, external walls, skylights, or roof panels must receive particular attention in sensor placement to capture the thermal impact of the Philippine sun.

Freezer Storage Areas (-20°C and Below)

Freezer storage areas for pharmaceutical products — plasma products, certain vaccines, some biologics — require the same systematic thermal mapping approach, conducted at the specified temperature range. The power failure test is particularly important for freezer storage, where temperature recovery after a failure is slower and the window for intervention before product damage is narrower.

Ultra-cold storage (-60°C to -80°C) for mRNA vaccines and some gene therapy products represents the most demanding environment for thermal mapping in the Philippine pharmaceutical sector. The specialised equipment required for these studies and the technical expertise needed to interpret the results make working with an experienced metrology service provider essential.

Drug Storage Rooms in Hospital Pharmacies

Hospital pharmacies in the Philippines must maintain a range of storage conditions — ambient, refrigerated, and sometimes frozen — for the products they dispense. The Philippine FDA and DOH requirements for hospital pharmacies increasingly expect documented temperature control of all storage areas, including mapping documentation for cold storage units.

Hospital pharmacies are a frequently overlooked area for thermal mapping compliance. The focus of most hospital QA programmes is on the pharmacy dispensing process rather than the physical storage environment. But the products stored in hospital pharmacy refrigerators — vaccines for ward administration, injectable biologics, blood-derived products — are among the most temperature-sensitive in the entire pharmaceutical supply chain.

Distribution Centres and 3PL Cold Chain Warehouses

Third-party logistics providers operating pharmaceutical cold chain warehouses in the Philippines are subject to the same thermal mapping requirements as manufacturers and distributors. Multinational pharmaceutical companies using 3PL warehousing increasingly require their 3PL partners to provide thermal mapping qualification reports as a condition of their distribution agreements.

For 3PL providers, thermal mapping documentation is also a key differentiator in business development. The ability to present a comprehensive, GMP-quality thermal mapping report — covering seasonal studies, power failure testing, and permanent sensor placement — demonstrates the level of quality assurance investment that sophisticated pharmaceutical clients expect.

7. What FDA Inspectors Look for During a Pharmaceutical Warehouse Inspection

Understanding what Philippine FDA inspectors evaluate during a pharmaceutical warehouse inspection enables you to prepare your documentation systematically. Based on the regulatory requirements of FDA Circular 2021-003, WHO GDP guidelines, and GMP standards, here are the key documentation elements that will be reviewed.

Documentation Checklist: What to Have Ready

• Thermal mapping reports — complete reports for all mapping studies conducted, including seasonal studies, with all sensor calibration certificates attached
• Protocol approval records — signed protocols for each mapping study, approved before the study began
• Equipment calibration certificates — current, traceable calibration certificates for all permanent monitoring sensors
• Temperature monitoring records — continuous temperature logs for all storage areas for the period under review, demonstrating that temperatures were maintained within specifications
• Temperature excursion records — documentation of all excursion events, investigations, corrective actions, and product disposition decisions
• Change control records — documentation of any changes to the warehouse or HVAC system, with impact assessments and remapping decisions
• Requalification schedule — evidence that periodic requalification is planned and tracked
• Excursion response SOP — the written procedure for responding to temperature alarms and excursions, with training records
• Qualified Person / QA Manager qualification records — evidence that the person responsible for GMP compliance has appropriate qualifications

Common FDA Inspection Findings in Philippine Pharmaceutical Warehouses

The following are the most frequently cited deficiencies in Philippine pharmaceutical warehouse temperature control inspections:

• No thermal mapping study conducted — the warehouse has been in operation without ever having been qualified through a mapping study
• Mapping study conducted without a formal approved protocol — the study lacks documentation of how it was designed and what acceptance criteria were used
• Data loggers used without current calibration certificates — the mapping data cannot be relied upon because the measurement instruments were not verified to be accurate
• Single-season mapping only — the study was conducted once, not in both dry season and wet season conditions
• Monitoring sensors not positioned at hot spot and cold spot — sensors were placed by intuition rather than based on mapping data, creating a risk that worst-case zones are unmonitored
• No power failure test data — the time-to-excursion window has not been established, so the excursion response SOP has no scientific basis for its response time requirements
• Excursions documented but not investigated — temperature alarms triggered but no investigation records exist
• Mapping reports filed but not reviewed by QA — the reports exist but show no evidence of review, approval, or use in driving quality decisions

8. How to Choose a Thermal Mapping Service Provider for Your Philippine Pharmaceutical Warehouse

The quality of your thermal mapping study is only as good as the service provider conducting it. In the Philippine pharmaceutical sector, the consequences of a poorly conducted mapping study are serious — a study that looks complete but was not conducted according to WHO and GMP standards may not protect you during an FDA inspection. Here is what to evaluate when selecting a thermal mapping service provider.

Non-Negotiable Criteria

• PAB-accredited calibration: All data loggers used in your mapping study must be calibrated by a laboratory accredited by the Philippine Accreditation Bureau (PAB) to ISO/IEC 17025. Ask to see current PAB accreditation certificates before engaging any provider. Without this, your study cannot demonstrate the measurement traceability required by WHO and GMP standards.
• Formal protocol development: Your provider must develop and submit a written mapping protocol for your approval before the study begins. Any provider who starts placing sensors without presenting a protocol for your review is not following WHO or GMP best practice.
• GMP-quality reporting: Request a sample report before engagement. The report must contain all the elements described in Section 4 of this guide, formatted to meet the documentation standards of a GMP quality management system.
• Pharmaceutical sector experience: Thermal mapping for pharmaceutical warehouses is technically distinct from mapping for food or general cold chain applications. Your provider must have specific experience with pharmaceutical GMP requirements, WHO TRS 961, FDA Circular 2021-003, and ISPE standards.
• Seasonal mapping programme: Your provider must understand and advise on the Philippine seasonal mapping requirement. A provider who recommends a single-season study without flagging the need for seasonal coverage does not understand the WHO requirements applicable to your climate.

Why Metrologie Solutions Philippines Is the Right Choice for Your Pharmaceutical WarehouseMetrologie Solutions Philippines combines ISO/IEC 17025-traceable calibration, deep pharmaceutical GMP expertise, and thorough knowledge of FDA Circular 2021-003 and WHO TRS 961 requirements.We serve drug manufacturers, importers, distributors, hospital pharmacies, and cold chain 3PL providers across the Philippines. Our thermal mapping studies are designed from the ground up to produce the documentation pharmaceutical companies need for LTO compliance, FDA inspections, and multinational principal audits.Every study includes: written protocol with QA approval workflow, PAB-traceable calibration certificates for all sensors, seasonal mapping recommendations, power failure testing, permanent sensor placement guidance, and a complete GMP-quality report.Contact us at metrologiesolutions.com to discuss your pharmaceutical warehouse thermal mapping requirements.

9. Frequently Asked Questions: Pharmaceutical Warehouse Thermal Mapping in the Philippines

Does every pharmaceutical warehouse in the Philippines need thermal mapping?

Yes. Any pharmaceutical establishment storing temperature-sensitive products — whether manufacturer, importer, distributor, hospital pharmacy, or 3PL cold chain operator — must demonstrate that its storage areas maintain the required temperature conditions. This demonstration requires a thermal mapping study. FDA Circular 2021-003 and WHO Good Distribution Practice guidelines both require this qualification as a condition of pharmaceutical storage operations.

How long does a pharmaceutical warehouse thermal mapping study take?

The active data collection phase typically takes five to seven days for a standard pharmaceutical warehouse. However, the full programme — from protocol development through report delivery — typically requires two to four weeks, depending on the size and complexity of the facility and the number of storage areas being mapped. Seasonal mapping adds additional studies that are typically conducted three to six months after the initial study.

How much does pharmaceutical warehouse thermal mapping cost in the Philippines?

The cost of a thermal mapping study depends on the size of the storage area, the number of storage zones to be mapped, the number of sensors required, and the level of documentation detail required by your quality system. Contact Metrologie Solutions Philippines for a detailed, transparent quotation tailored to your specific warehouse requirements.

Can we conduct the thermal mapping study ourselves, or must we use an external provider?

While it is theoretically possible for a well-equipped internal QA team to conduct a thermal mapping study in-house, most Philippine pharmaceutical companies use external specialist service providers for their mapping studies. The reasons are practical: external providers typically have the specialised, calibrated equipment required; their calibration certificates carry the independent traceability assurance that FDA inspectors expect; and the external perspective provides additional credibility to the study conclusions. For studies intended to satisfy FDA LTO requirements or WHO GDP obligations, using a specialist external provider is strongly recommended.

What happens if our warehouse fails the thermal mapping study?

If the study reveals that any part of your warehouse does not consistently maintain the required temperature range — due to hot spots, cold spots, or other temperature distribution problems — you must take corrective action before pharmaceutical products are stored there. Corrective actions may include HVAC system adjustment or replacement, installation of air baffles or circulation fans, relocation of shelving, improvement of insulation, installation of air curtains on loading dock doors, or changes to operating procedures (such as limiting the duration of door openings). After corrective actions are implemented, a new mapping study must be conducted to confirm that they were effective.

How should we handle temperature excursions discovered during or after the mapping study?

Excursions discovered during a mapping study — periods when any sensor recorded temperatures outside the acceptance criteria — must be documented in the mapping report and investigated. If excursions were due to controlled study conditions (such as deliberate door openings to simulate normal operations), they may be acceptable if they are brief and their impact on product stability has been evaluated. If excursions reflect systematic failure of the storage environment to maintain required temperatures, corrective action is required before the facility can be qualified.

Does our hospital pharmacy need thermal mapping for its pharmaceutical refrigerators?

Yes — if your hospital pharmacy refrigerators are used to store regulated pharmaceutical products such as vaccines, biologics, injectable antibiotics, or blood products, then temperature distribution qualification of those units is expected under both Philippine FDA and WHO standards. For smaller refrigerators, a simplified mapping protocol may be appropriate, but the fundamental requirements — calibrated sensors, documented study, identified hot and cold spots, and permanent sensor placement at worst-case locations — still apply.

Conclusion: Thermal Mapping Is Your Foundation for Pharmaceutical Compliance in the Philippines

For every pharmaceutical company operating in the Philippines — whether you manufacture, import, distribute, or dispense — temperature control of your storage facilities is one of the most fundamental obligations of your licence to operate. The Philippine FDA is clear about this. WHO Good Distribution Practice guidelines are clear about this. And the multinational pharmaceutical principals whose products you handle are increasingly clear about this.

Thermal mapping is not a bureaucratic exercise. It is the scientific process by which you prove — with data, documentation, and independently traceable measurements — that your pharmaceutical warehouse actually does what it claims to do: protect the temperature integrity of the medicines in your care.

A pharmaceutical company that has conducted rigorous, documented, seasonal thermal mapping of its storage facilities is a company that has made a genuine commitment to product quality and patient safety. It is also a company that can face an FDA inspection with confidence, present its documentation to international principals with pride, and build a reputation in the Philippine pharmaceutical market for the kind of quality assurance that clients trust.

Metrologie Solutions Philippines exists to help Philippine pharmaceutical establishments achieve and maintain this standard. Our thermal mapping studies are conducted with PAB-traceable calibration, designed to meet FDA Circular 2021-003 and WHO TRS 961 requirements, and documented to GMP standards that will satisfy the most rigorous regulatory review.

Take the First Step TodayContact Metrologie Solutions Philippines to schedule a consultation for your pharmaceutical warehouse thermal mapping programme. We will assess your facility, advise on the appropriate scope and methodology for your specific regulatory obligations, and provide a transparent quotation for a thermal mapping study that meets every requirement your business faces.Website: metrologiesolutions.com   |   Services: Pharmaceutical Warehouse Thermal Mapping · Calibration · Training · Monitoring System Consultation

About Metrologie Solutions PhilippinesMetrologie Solutions Philippines is the country’s premier provider of thermal mapping services, instrument calibration, and metrology training. We specialise in pharmaceutical warehouse qualification, cold chain validation, and ISO/IEC 17025-traceable calibration across the Philippines. Our team has served drug manufacturers, importers, distributors, hospitals, and 3PL cold chain operators with rigorous, documentation-ready mapping studies that satisfy FDA, WHO, and GMP requirements.Website: metrologiesolutions.com   |   Services: Thermal Mapping · Calibration · Training · Monitoring Consultation

Tags: thermal mapping pharmaceutical Philippines, pharma warehouse temperature mapping, FDA Philippines temperature mapping, FDA Circular 2021-003 Philippines, WHO thermal mapping requirements Philippines, GMP temperature validation Philippines, pharmaceutical cold storage Philippines, temperature mapping drug distributor Philippines, cold chain compliance Philippines, pharmaceutical warehouse compliance Philippines, ISO/IEC 17025 calibration Philippines, Metrologie Solutions Philippines